Skip to main content

Alzheimer's Disease, Dementia & Cognitive Disorders

March 04, 2020
Low-cost, noninvasive cognitive testing may help identify people at risk of progressing to the first stage of Alzheimer’s disease, according to a study published online in Biological Psychiatry.
January 13, 2020
Cognitive aging appears to occur more rapidly in people with psychotic disorders, compared with peers without such disorders, according to a study that followed 445 people for 2 decades after their first psychotic disorder hospitalization.
October 23, 2019
Biogen Inc revived plans on Tuesday to seek U.S. approval for Alzheimer's treatment aducanumab, surprising investors and saying data from more patients in two discontinued studies showed the drug reduced the decline of patients.
October 22, 2019
Maladaptive personality traits while in high school may be independent risk factors for dementia a half-century later, according to a study published online in JAMA Psychiatry.
October 11, 2019
For older adults, hearing aids may delay some forms of mental and physical decline associated with hearing loss and aging, a US study suggests.
October 09, 2019
SAN DIEGO—While medications can address some of the symptoms of Alzheimer’s disease, maintaining a healthy lifestyle can delay its onset and slow progression of the disease, a geriatric psychiatry expert told attendees at Psych Congress 2019.
October 03, 2019
Most older adults who have one or two drinks a day are no more likely to develop cognitive decline or dementia than their peers who drink only rarely, a recent study suggests.
October 01, 2019
Dementia patients and the family members who care for them may have a better quality of life when they have access to telephone and online support, new research suggests.
September 25, 2019
In people at high risk of Alzheimer’s disease, a half hour of aerobic exercise 4 to 5 times a week may delay brain deterioration, according to a proof-of-concept study published online in the Journal of Alzheimer’s Disease.
September 13, 2019
Biogen Inc and partner Eisai Co Ltd said they would abandon two late-stage trials testing experimental Alzheimer's treatment elenbecestat, months after scrapping trials of another drug for the memory-robbing disease.
Back to Top